NCT05236738View on ClinicalTrials.gov

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

July 5, 2022

Study Completion Date

July 26, 2022

Conditions
Healthy Participants
Interventions
DRUG

Atazanavir

Specified dose on specified days

DRUG

Cobicistat

Specified dose on specified days

DRUG

Atazanavir/Cobicistat Mini-tablet

Specified dose on specified days

Trial Locations (1)

33136

Local Institution - 0001, Miami

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05236738 - A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions | Biotech Hunter | Biotech Hunter